

ASTrID – a paradigm shift for sepsis diagnostics



ASTrID® in short

- Technology eliminating the need for traditional blood culturing
- Identification of pathogens in 4 hours, and a phenotypic antibiotic susceptibility profile in an additional 6 hours
- “One-stop-shop” with the most comprehensive panel on the market
- Fully automated, 6 sample capacity with random access loading



Detection direct
from patient



Pathogen
identification




Antibiotic
susceptibility testing

Hours instead of days


Q-linea's fully automated solutions will determine a sepsis diagnosis in the shortest possible time.

ASTar will deliver answers about antibiotic susceptibility directly from positive blood cultures while the ASTRiD platform will identify the cause of sepsis and an antibiotic susceptibility profile directly from venous blood.

ASTriD®



ASTar™



www.qlinea.com

Q-linea and ASTRiD are registered trademarks and ASTar is a trademark of Q-linea AB.
© Q-linea 2017. First published May 2017.
Q-linea AB, Dag Hammarskjölds väg 54 B, SE 752 37 Uppsala, Sweden.

Q-LINEA 